TLX — Telix Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- AU$3.39bn
- AU$3.85bn
- $803.79m
Annual cashflow statement for Telix Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | R2023 December 31st | R2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | fx Final | fx Final | Final | Final | Final |
| Changes in Working Capital | 9.1 | 13.1 | -9.85 | -16.7 | -45.9 |
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -44.5 | -44.3 | 14.3 | 27.5 | -17.3 |
| Capital Expenditures | -1 | -9.61 | -7.11 | -30.6 | -56 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -1.04 | -2.17 | -9.73 | -56.1 | -230 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -2.05 | -11.8 | -16.8 | -86.7 | -286 |
| Financing Cash Flow Items | 0 | -5.42 | 0 | -9.71 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 2.14 | 121 | 7.09 | 417 | -3.72 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -42 | 65.4 | 5.52 | 356 | -298 |